Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
Want to see DE:LS60 full AI Analyst Report?
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.19 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€10.83M
Enterprise Value€76.24M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetA virtually debt-free balance sheet materially lowers financial risk and interest burden, providing durable flexibility to fund clinical trials, commercialization, or bridge operating losses via equity rather than costly debt. This structural cushion supports execution through multi-quarter commercialization cycles.
Recurring Revenue Potential From Consumables And ServicesA business model with installed systems plus per-procedure consumables and service creates a durable revenue tail once clinical sites scale. Recurring disposables and maintenance generate predictable, higher-margin revenue over time and help monetize installed base as procedure volumes grow.
Specialized Clinical Technology With Integration And CollaborationsNiche, image-guided laserthermia and active clinical collaborations create barriers to entry and higher switching costs for hospitals. Durable advantages include clinical validation, workflow integration, and technical specialization that can sustain adoption advantages and justify deepening hospital relationships over years.
Bears Say
Deep And Persistent LossesLarge, sustained net losses erode equity and constrain the company's ability to self-fund commercialization, R&D, and scaling. Without a clear path to durable positive margins, ongoing losses increase financing needs, raise dilution risk, and limit long-term operational flexibility.
Consistent Negative Operating And Free Cash FlowPersistent negative OCF/FCF means core operations do not generate cash to sustain growth. This structural cash burn necessitates external financing or depleting reserves, constraining investment in market development, lengthening time to profitability, and elevating execution risk over quarters.
Small, Volatile And Declining Revenue BaseA small, non‑linear revenue base reduces operating leverage and makes gross-margin recovery difficult. Declining top-line in 2025 signals adoption headwinds or concentration risks; without steady revenue growth, scaling fixed costs and achieving sustainable margins will remain challenging over the medium term.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.19 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €10.83M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is May 15, 2026 which is in 9 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Feb 20, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.035.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.125%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―